BioAge Labs, Inc. (BIOA) Earnings Call Transcripts

BioAge Labs, Inc.'s Latest Earnings Call - May 8, 2026

In the first quarter of fiscal year 2026, BioAge Labs, Inc. reported significant advancements in its lead program, BGE-102, an oral NLRP3 inhibitor. The company highlighted an 86% reduction in CRP levels among obese subjects during Phase I trials, indicating potential best-in-class efficacy for treating cardiovascular and retinal diseases. Management maintained its guidance for upcoming clinical trials, signaling confidence in the drug's development timeline and its potential market impact. The stock could be positively influenced by these promising clinical results and the strategic focus on expanding therapeutic indications.

Reported metrics

Guidance from management

Management maintained guidance for upcoming trials, indicating confidence in the timelines for the cardiovascular risk study and the DME study, both expected to yield data in 2026.

What management said

Yes. I mean we haven't looked at specific brain regions in general. We have done some experiments proving that this drug is centrally active, and you can get with systemic administration, you can get decreases in Island beta within the brain. So we've proven that, that that's the case. We've spoken to a number of experts specifically in this regard. And what our understanding is the levels in the CSF correlate very h...

Next up, Mike Ulz from Morgan Stanley. Seen is there are multiple doses that show significant reductions in CRP and favorable safety. Can you talk about the strategic advantages 102 could offer with potential dosing flexibility as you think about development in different patient populations?

What analysts pressed on

Analysts expressed concerns about the long-term safety of chronic NLRP3 inhibition and whether the efficacy seen in Phase I trials can be replicated in larger Phase II studies. There are also questions regarding patient adherence to oral therapies compared to injectable options.

Main topics on the call

• Phase I Clinical Results — BioAge's Phase I study of BGE-102 demonstrated a robust safety profile and significant efficacy, with 'up to 86% CRP reductions in obese subjects.' Management noted that '87% of subjects achieved normalized CRP below 2 m...
• Therapeutic Pipeline Expansion — Management outlined plans to explore BGE-102 in both cardiovascular and ophthalmological indications, emphasizing its 'potential to address inflammation-driven diseases across multiple organ systems.' This dual focus cou...
• Upcoming Clinical Trials — BioAge is set to initiate a cardiovascular risk trial by the end of the year and a diabetic macular edema (DME) trial mid-year, with results expected in 2026. Management stated, 'We believe we can pursue not only seconda...
• Safety and Tolerability — The Phase I study reported that 'all adverse events were mild to moderate' and comparable to placebo, indicating a favorable safety profile for BGE-102. This is crucial for future patient acceptance and market adoption.

Read the full BioAge Labs, Inc. transcript (May 8, 2026) → Summary generated from the call transcript; every figure above is stated by management on the record.

Earnings Call History

EarningsCalls.dev has 3 BioAge Labs, Inc. earnings call transcripts on record, spanning April 21, 2026 to June 8, 2026. Based on this history, BioAge Labs, Inc. reports quarterly. The most recent call on file is dated June 8, 2026. The full list is below — each row opens the complete, free-to-read transcript.

Ticker

BIOA

Exchange

NasdaqGS

Country

US

Sector

Health Care

Industry

Pharmaceuticals

Calls on record

3

First call

April 21, 2026

Most recent

June 8, 2026

Reporting cadence

quarterly